Furthermore, our study suggests that I3C mitigates AD-related skin inflammation by downregulating TSLP/periostin expression and inhibiting the signaling pathways associated with TSLP/periostin, including NF-κB and MAPK (depicted in Fig. 5). Here, NFKB1 is linked to dermatitis.